Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Madrigal Pharmaceuticals (MDGL) Debt to Equity (2022 - 2025)

Historic Debt to Equity for Madrigal Pharmaceuticals (MDGL) over the last 10 years, with Q3 2025 value amounting to $0.54.

  • Madrigal Pharmaceuticals' Debt to Equity rose 26039.1% to $0.54 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.54, marking a year-over-year increase of 26039.1%. This contributed to the annual value of $0.16 for FY2024, which is 4529.76% down from last year.
  • Per Madrigal Pharmaceuticals' latest filing, its Debt to Equity stood at $0.54 for Q3 2025, which was up 26039.1% from $0.17 recorded in Q2 2025.
  • Madrigal Pharmaceuticals' Debt to Equity's 5-year high stood at $5.16 during Q3 2023, with a 5-year trough of $0.14 in Q2 2024.
  • Over the past 4 years, Madrigal Pharmaceuticals' median Debt to Equity value was $0.27 (recorded in 2022), while the average stood at $0.99.
  • In the last 5 years, Madrigal Pharmaceuticals' Debt to Equity crashed by 9707.82% in 2024 and then soared by 26039.1% in 2025.
  • Over the past 4 years, Madrigal Pharmaceuticals' Debt to Equity (Quarter) stood at $0.25 in 2022, then grew by 14.1% to $0.28 in 2023, then tumbled by 45.3% to $0.16 in 2024, then surged by 248.4% to $0.54 in 2025.
  • Its Debt to Equity was $0.54 in Q3 2025, compared to $0.17 in Q2 2025 and $0.17 in Q1 2025.